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1. Introduction 
Venous Thromboembolism (VTE) is a common complication following orthopaedic 
procedures. It is discussed most commonly as it relates to total hip arthroplasty (THA) and 
total knee arthroplasty (TKA), though this disease process can be seen after any orthopaedic 
surgery. It is associated with significant morbity and costs (Caprini et al., 2003). This chapter 
will provide an overview of the epidemiology, pathophysiology, and management of 
thromboembolic disease. This will include preventative strategies, evidence-based 
guidelines and a focus on newer drug agents currently being developed. 
2. Epidemiology 
Total joint arthroplasties remain some of the most common orthopaedic procedures 
performed worldwide. It is estimated that by 2015, over 500,000 total hip arthroplasties 
and 1.3 million total knee arthroplasties will be done in the United States alone (Kim, 
2008). The aggregate costs in 2007 totaled over $15 billion (US Agency for Healthcare 
Research and Quality, 2007). Geerts et al. reported that VTE would occur in 40%-60% of 
the patients undergoing total joint arthroplasty if no prophylaxis was administered 
(Geerts et al., 2008). Despite appropriate chemophrophylaxis, one study noted 
asymptomatic proximal DVT found on ultrasound in 6.7% of THA and TKA patients at 
the time of transfer to a rehabilitation center (Schellong et al., 2005). As many as 80% of all 
clinical VTE events associated with arthroplasty patients occur within 3 months after 
surgery (Oster et al., 2004). 
The costs of VTE are significant. Approximately 10% of the patients who develop VTE 
following THAs or TKAs require re-admission to the hospital within 3 months after their 
index surgery (Oster et al., 2004). The clinical sequelae are often significant and can include leg 
swelling, venous stasis ulcers, pulmonary hypertension, post-thrombotic syndrome, and 
recurrence (Heit, 2006). The one-year mortality following deep vein thrombosis (DVT) has 
been reported as high as 14.6%. Pulmonary embolism (PE) is associated with even higher 
mortality rate. Heit et al. reported as high as 52.3% in a recent cohort study (Heit et al., 1999). 
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3. Pathophysiology 
The coagulation cascade is a complex system in which multiple components are activated to 
produce fibrin. An overview of the system along with the targets of various therapeutic 
interventions is shown in Figure 1. The coagulation pathway is separated into the intrinsic 
and the extrinsic pathways. The latter is activated in response to specific tissue injury. Both 
lead to the eventual formation of thrombin. Thrombin causes the conversion of fibrinogen to 
fibrin. Additionally, it activates factor XIII which stabilizes the fibrin. An endogenous 
fibrinolytic system balances this system. It consists of antithrombins, proteins C and S, and 
the plasmin-plasminogen system. 
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Fig. 1. Targets for anticoagulant drugs. LMWH = low-molecular-weight heparin. (Reference: 
Hoffman M, Dougald M. The action of high-dose factor VIIa in a cell-based model of 
hemostasis. Disease a Month 2003; 49: 14-21) 
The primary pathophysiology factors that predispose any patient to VTE are the Virchow’s 
Triad: endothelial injury, venous stasis (or turbulent blood flow), and hypercoagulability. 
Endothelial injury can occur due to manipulation, and retractor placement during surgery. 
Venous stasis can occur due to positioning and the use of a tourniquet. Hypercoagulability 
can occur as a result of depletion or dilution of endogenous anticoagulants. It is also 
associated with several pro-coagulant disease processes such as factor V Leiden deficiency, 
protein C and S deficiency, and others. 
3.1 Natural history 
The natural history of venous thromboembolism is variable. There are four potential 
outcomes when thrombosis occurs. The thrombus can propagate, embolize, organize, or 
undergo fibrinolysis. Proximal thrombi are more likely to propagate and embolize than the 
smaller distal thrombi in general. 80% of symptomatic DVTs involve the proximal veins 
(Conduah & Lieberman, 2007). 
4. Prevention 
Clinical VTEs occur due to many different causes, but one significant factor is inadequate 
prophylaxis (Amin et al., 2010). Several barriers exist for inadequate prophylaxis. These 
include: expense, bleeding concerns, availability of agents, and conflicting 
recommendations. The American College of Chest Physicians (ACCP) and the American 
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Academy of Orthopaedic Surgeons (AAOS) have each released separate guidelines 
regarding the prevention of VTE. This can be confusing to the providers.  
Controversies exist regarding the two major practice guidelines for VTE prophylaxis. The 
ACCP has been updating its recommendations every 3 years for over 25 years (Hirsh et al., 
2008). The AAOS guidelines have been a more recent development. Though the two have 
many similarities, there are a few significant differences. A major area of disagreement 
involves the use of DVT as a surrogate for PE in arthroplasty patients. The AAOS guidelines 
do not emphasize the correlation between DVT and pulmonary embolism (Eikelboom et al., 
2009). In fact, the AAOS guidelines are for the prevention of PE following joint arthroplasty. 
The ACCP recommendations focus on the prevention of both VTE and PE as the goal rather 
than PE alone in the AAOS guidelines. Both guidelines focus on a balance between the risk 
of bleeding and the efficacy of anticoagulation. They both define risk-to-benefit ratio for 
different agents. Some of the most clinically relevant differences between the two guidelines 
are presented in Table 1. Neither guideline has been universally accepted. A recent survey 
was conducted by the American Association of Hip and Knee Surgeons regarding the 
practice standards among its member surgeons. The data demonstrated that 74% of the 
hospitals had adopted the ACCP guidelines, while 68% of the surgeons preferred the AAOS 
guidelines (Markel et al., 2010). 
Furthermore, compliance with the current guidelines has been suboptimal. Many surgeons 
continue to under-appreciate the prevalence of VTE and remain concerned with 
postoperative bleeding. Additionally, patient factors can inhibit appropriate prophylactic 
treatment. Injectable agents are expensive. Moreover, some patients are not at ease or in 
compliance with their administration. Oral agents have the challenges including: titration, 
monitoring, and drug-drug, or drug-food interaction (Moyer et al., 2009).  
4.1 Extended duration prophylaxis 
The ACCP guidelines recommend the optimal duration of VTE prophylaxis to be 28 to 35 
days following THAs, and 10 to 14 days following TKAs (Kolb et al., 2003). Currently, the 
mean length of hospital stay is between 3 to 4 days, therefore full compliance with this 
recommendation is difficult for both the patient and the provider. Several studies have 
reported that continuation of thromboprophylaxis beyond the hospitalization is efficacious 
and safe in the risk reduction of late VTE in surgical patients (Planes et al., 1996; Lassen et 
al., 1998; Comp et al., 2001; Bergqvist et al., 2002; Rasmussen et al., 2006). 
Extended duration prophylaxis for VTE requires proper selection of pharmacological 
agent(s). The ideal anticoagulant should have the following characteristics: standard dosing 
with self-administration, no requirement for monitoring, established efficacy and safety 
profiles, acceptable tolerability in populations with co-morbid conditions, and few drug-
drug or drug-foot interactions. The ACCP guidelines currently recommend warfarin, low-
molecular weight heparins (LWMH), and fondaparinux. They specifically recommend 
against using aspirin alone in the high-risk orthopedic patient population as there are 
insufficient evidence-based data. 
The AAOS guidelines recommend 2 to 6 weeks of prophylaxis with warfarin, 6 weeks using 
aspirin, or 7 to 12 days using LMWH or fondaparinux (AAOS 2007). The ACCP guidelines, 
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in contrast, recommend pharmacological thromboprophylaxis for up to 35 days after THA 
and for 10 to 35 days after TKA. Moreover, they recommend against the use of aspirin in 
this patient population. 
ACCP
Recommendation Risk Reccommendation
PE Bleeding
Aspirin
LMWH
Fondaparinux
LMWH
Warfarin
Aspirin
Warfarin
Fondaparinux
Aspirin
Warfarin
None
Fondaparinux 
Warfarin      
LMWH Standard Elevated
Elevated Elevated
AAOS
Standard Standard
Elevated Standard
 
Table 1. Summary of ACCP and AAOS recommendations for pharmacologic 
thromboprophylaxis in patients undergoing elective hip or knee surgery. (Reference: Huo 
M. VTE prophylaxis after total joint arthroplasty: current challenges-potential solutions. 
Current Orthopaedic Practice 2011;22:193-197.) 
4.2 Quality measures 
Over the past 5 years, quality measures have been proposed and put into clinical application 
to monitor compliance with best practice guidelines in VTE prophylaxis. The Surgical Care 
Improvement Project (SCIP) was created in 2006 with reduction of VTE being one of its four 
primary focus areas. The Center for Medicare and Medicaid Services (CMS) has declared 
postoperative VTE as a “never event.” As such, the CMS will no longer reimburse the 
hospital the costs associated with these complications. Other agencies and consumer groups 
have also declared VTE as a preventable complication.  
Several important improvements have already occurred as a result of these outcome 
measures. Surgeons and administrators have collectively established hospital-wide or 
hospital system-wide prophylaxis protocols. They have also worked to establish training 
and education programs to deliver the best practice guidelines to all the staff involved in 
patient care. Several limitations still exist however. The AAOS and the ACCP guidelines 
should be modified to establish a consensus. Unmet needs and improvement in the safety 
profiles hopefully will be fulfilled by newer agents in clinical development (Huo, 2011a). 
4.3 Specific modalities 
A summary of specific oral pharmacologic agents currently in clinical application for 
orthopedic patients is in Table 2. 
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Drug Mechanism Dosing Monitoring Half Life Renal Clearance
Warfarin
Vitamin K 
antagonist
Variable; 
Daily
Yes 40 hours 0%
Dabigatran 
etexilate
Factor IIa 
inhibitor
Fixed; 
Twice Daily
No
14-17 
hours
100%
Apixaban
Factor Xa 
inhibitor
Fixed; 
Twice Daily
No
9-14 
hours
25%
Rivaroxaban
Factor Xa 
inhibitor
Fixed; Once 
Daily
No 9 hours 65%
 
Table 2. Comparison of warfarin to new oral anticoagulants. (Reference: Eikelboom JW. 
Weitz JI. A replacement for warfarin: the search continues. Circulation 2007;116:131-133.) 
4.3.1 Mechanical 
Mechanical prophylaxis using sequential compressive devices (SCDs) or foot pumps can be 
used as a sole means of VTE prophylaxis. Their clinical efficacy and safety have been 
documented in multiple studies. This is particularly useful in a patient that is perceived to 
have an elevated bleeding risk (Geerts et al., 2008). In many practices, mechanical devices 
are often used in conjunction with pharmacological prophylaxis. Newer devices may be 
used in the outpatient setting upon hospital discharge. The clinical efficacy, safety, and 
compliance have been documented in a few studies. It is necessary to continue to follow 
larger cohorts of patients using outpatient mechanical prophylaxis alone to fully determine 
the efficacy and compliance.  
4.3.2 Warfarin 
Warfarin has been used as VTE chemoprophylaxis in high-risk orthopedic patients for 
decades. It is an efficacious agent. However, it requires close monitoring. It can be both 
difficult and costly in the outpatient setting (Eikelboom & Weitz, 2007). It also has numerous 
drug-drug and drug-food interactions. These interactions can be particularly challenging 
considering the issue of poly-pharmacy in the elderly joint arthroplasty patient population. 
It also has a delayed onset of action, which may require bridging with a shorter acting 
anticoagulant such as LMWHs or unfractionated heparin. A recent paper by Caprini et al. 
noted that physicians often used inadequate bridging protocols in the postoperative period. 
This can have important clinical implications. They found that the 30-day mortality rate was 
found to be 6% for DVT and 12% for PE in this cohort (Caprini et al., 2005). 
4.3.3 Aspirin 
The ACCP guidelines do not recommend using aspirin alone in any of the high-risk 
orthopedic patient populations. The AAOS guidelines do sanction its use in patients with 
standard risk profile for pulmonary embolism prevention (Geerts et al., 2008). 
4.3.4 Unfractionated heparin 
This has been included in the ACCP guidelines for patients undergoing general surgery 
procedures. However, the ACCP guidelines have recommended against using 
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unfractionated heparin alone in total joint arthroplasty or hip fracture patients due to 
inadequate evidence-based data to support its efficacy in these patient populations (Geerts 
et al., 2008). 
4.3.5 Low-molecular-weight heparin 
In contrast to warfarin, LMWHs have a predictable dose response with few interactions. 
Self-administration is generally well-tolerated and acceptable patient compliance has been 
documented in several studies. Additionally, there is no need for monitoring (Noble & 
Finlay, 2005). Dose adjustment may be necessary in the elderly, in particular in those with 
compromised renal clearance. LMWHs have considered to be the standard-of-care in many 
medical communities (Geerts et al., 2008). 
5. Newer agents 
There are several new oral anticoagulants in various stages of clinical development. These 
new classes target the inhibition of either thrombin or factor Xa. Most of the clinical trial 
data have demonstrated equal or even superior efficacy in comparison to LMWH. However, 
bleeding complications remain the primary concern. There are several other potential 
complications that have been reported.  
5.1 Newer agents of historic importance 
Ximelagatran was the first direct-thrombin inhibitor, and was approved initially by the 
European regulatory agencies. The initial trials showed no signs of liver toxicity in short-
term use of up to 11 days (Eriksson et al., 2003). However, extended treatment (greater than 
35 fays) was found to be associated with an increased risk of liver toxicity in one study 
(Agnelli et al., 2009). The liver toxicity was unpredictable, and the product was later 
withdrawn from the market (Vaughan, 2005). 
Razaxaban was the first oral Factor Xa inhibitor to be developed. Data from phase I clinical 
trials demonstrated adequate efficacy and safety (Spyropoulos, 2007). A phase II trial 
involving TKA patients demonstrated significantly higher bleeding complication rates when 
compared with enoxaparin (Lassen et al., 2003). The trial was terminated prematurely and 
the drug development was discontinued. 
5.2 Current oral anticoagulants 
Dabaigatran etexilate is a pro-drug of the direct thrombin inhibitor, dabigatran (Eriksson et 
al., 2004). There have been four phase III clinical trials comparing this drug to enoxaparin. In 
addition, a meta-analysis of three of these has been conducted (Wolowacz et al., 2009). It 
demonstrated non-inferiority to once-daily enoxaparin 40mg dose in one clinical trial 
involving THA, but failed to do so when compared to twice-daily enoxaparin dosing with 
30mg Additionally, it demonstrated non-inferiority to once-daily enoxaparin 40mg dose in 
two clinical trials involving THA patients (Eriksson et al., 2007a; Eriksson et al., 2007b). It 
was approved in the European Union and in Canada in 2008 for use in total joint 
arthroplasty patients as VTE prophylaxis. In the United States, it was approved for use in 
certain atria fibrillation patients for stroke prevention (Huo, 2011b). 
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Rivaroxaban and apixabab are both inhibitors of factor Xa. Their mechanism involves the 
inhibition of circulating factor Xa as well as bound factor Xa within the prothrombinase 
complex (Weitz, 2006). There have been four phase III clinical trials comparing rivaroxaban 
to enoxaparin (Eriksson et al., 2008). It also is approved in the European Union and Canada 
for VTE prophylaxis in patients undergoing THAs and TKAs. It has recently been approved 
in the United States.  
Apixaban has been evaluated in several phase III clinical trials as well. It has not been 
approved for use anywhere (Lassen et al., 2010a). It was found to be more efficacious than 
once-daily dosing of enoxaparin, but failed to demonstrate non-inferiority to twice daily 
dosing of enoxaparin (Lassen et al., 2009; Lassen et al 2010b). 
5.2.1 Potential problems with the newer agents 
Bleeding events are the most important complication. A recent survey reported that 50% 
or more orthopaedic surgeons in the United States stated that they were more concerned 
with bleeding than the risk of VTE (Anderson et al., 2009). Major bleeding has occurred 
with all of these agents as it has with other pharmacological agents. LMWHs have been 
studied for over 20 years, and the incidents of significant bleeding complications ranges 
from 0.9% to 9.3% (Leizorovicz et al., 1992). A major difference between LMWH and the 
newer agents is that enoxaparin can be at least partially reversed using protamine in 
certain situations (Crowther et al., 2002). The thrombin and factor Xa inhibitors have no 
such reversal agents yet (Ng & Crowther, 2006). An overview of the bleeding in clinical 
trials involving new agents is included in Table 3. It is also important to note the effect of 
drug-drug interactions. There have been trials showing prolonged bleeding when 
rivaroxaban was taken with clopidogrel or aspirin (Perzborn et al., 2007). Though there 
may be a relationship between bleeding and infection, the use of anticoagulation has not 
specifically been associated with a higher infection rate (Parvizi et al., 2007; Saleh et al., 
2002).  
Aside from bleeding risk, there are other adverse effects that have been documented with 
the thrombin and factor Xa inhibitors. Drug-induced liver toxicity is the most common 
reason cited for the withdrawal of a drug from the market (Lee, 2003). The exact mechanism 
has not been identified. There have been several trials with dabigatran that reported 
elevated liver enzymes, but all returned to baseline within 2 months (Eriksson et al., 2007b). 
Dabigatran is a substrate for the cellular transporter P-glycoprotein which could be a 
mechanism of drug interaction (Aszalos, 2007). CYP240 enzymes are involved in the 
metabolism of both factor Xa inhibitors (Bayer Inc, 2010). Both factor Xa and thrombin 
inhibitors are excreted through the renal system, so this could potentially lead to 
complications. 
Both types of drugs are promising alternatives due to several characteristics. They have 
predictable pharmacokinetics, few drug interactions, and no monitoring is required (Weitz 
et al., 2008). It is important to note that a perfect anticoagulant does not exist at this point. 
The thrombin and facto Xa inhibitors have been shown to be effective and safe in multiple 
trials, but there still is a lack of data from community practice. 
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Drug Study
Number of 
Patients
Arthroplasty
Duration 
(Days)
Regimine 
(mg)
Major Clinically 
Significant 
Bleeding
Surgical Site 
Bleeding
Non-Major 
Clinically 
Relevant Bleeding
BISTRO I 
(Eriksson, 
2004)
289 Hip 6-10
Dab 12.5-, 25-
, 50-, 100-, 
150-, 200-, 
300-BID; and 
150-, 300-QD
2.4% Dab 150-QD N/A 2.4% Dab 150-QD
BISTRO II 
(Eriksson, 
2005)
1949 Hip and Knee 6-10
Dab 50-, 150-
, 225-BID; 
and 300-QD; 
Enox 40-QD
8.2% Dab 150-BID; 
8.3% Dab 300-QD; 
4.6% Enox
N/A
4.1% Dab 150-QD; 
4.9% Dab 300-QD; 
2.6% Enox
RE-NOVATE 
(Eriksson, 
2007a)
3463 Hip 28-35
Dab 150-, 220-
QD; Enox 40-
QD
6.0% Dab 150-QD; 
6.2% Dab 220-QD; 
5.1% Enox
N/A
4.7% Dab 150-QD; 
4.2% Dab 220-QD; 
3.5% Enox
RE-MODEL 
(Eriksson, 
2008b)
2076 Knee 6-10
Dab 150-, 220-
QD; Enox 40-
QD
8.1% Dab 150-QD; 
7.4% Dab 220-QD; 
6.6% Enox
N/A
6.8% Dab 150-QD; 
5.9% Dab 220-QD; 
5.3% Enox
RE-
MOBILIZE 
(Ginsberg, 
2009)
2596 Knee 12-15
Dab 150-, 220-
QD; Enox 30-
BID
3.1% Dab 150-QD; 
3.3% Dab 220-QD; 
3.8% Enox
N/A
2.5% Dab 150-QD; 
2.7% Dab 220-QD; 
2.4% Enox
ODIXa-
KNEE 
(Turpie, 
2005)
613 Knee 5-9
Riv 2.5-, 5-, 
10-, 20-, 30-
BID; Enox 30-
BID
2.9% Riv 5-BID; 
4.8% Enox
0% Riv 5-BID; 
1.9% Enox
2.9% Riv 5-BID; 
2.9% Enox
ODIXa-OD-
HIP 
(Eriksson, 
2006a)
845 Hip 5-9
Riv 5-, 10-, 
20-, 30-, 40-
QD; Enox 40-
QD
2.8% Riv 10-QD; 
5,1% Enox
N/A
2.1% Riv 10-QD; 
3.2% Enox
ODIXa-HIP 
(Eriksson, 
2006b)
704 Hip 5-9
Riv 2.5-, 5-, 
10-, 20-, 30-
BID; Enox 40 
QD
8.1% Riv 5-BID; 
1.5% Enox
2.2% Riv 5-BID; 
0.8% Enox
5.9% Riv 5-BID; 
0% Enox
Dose-
escalation 
study 
(Eriksson, 
2007c)
625 Hip 5-9
Riv 2.5-, 5-, 
10-, 20-, 30-
BID; 30-QD; 
Enox 40 QD
3.8% Riv 5-BID; 
1.9% Enox
2.5% Riv 5-BID; 
0% Enox
1.3% Riv 5-BID; 
1.9% Enox
RECORD1 
(Eriksson, 
2008)
4433 Hip 31-39
Riv 10-QD; 
Enox 40-QD
3.2% Riv; 2.5% 
Enox
N/A
2.9% Riv; 2.4% 
Enox
RECORD2 
(Kakkar, 
2008)
2457 Hip
31-39 
Riv; 10-
14 Enox
Riv 10-QD; 
Enox 40-QD
3.4% Riv; 2.8% 
Enox
N/A
3.3% Riv; 2.7% 
Enox
RECORD3 
(Lassen, 
2008)
2459 Knee 10-14
Riv 10-QD; 
Enox 40-QD
3.3% Riv; 2.8% 
Enox
N/A
2.7% Riv; 2.3% 
Enox
RECORD4 
(Turpie, 
2009)
3034 Knee 10-14
Riv 10-QD; 
Enox 30-BID
3.0% Riv; 2.3% 
Enox
N/A
2.6% Riv; 2.0% 
Enox
RECORD1-3 
(Eriksson, 
2009)
9349 Hip and Knee 10-39
Riv 10-QD; 
Enox 40-QD
3.3% Riv; 2.7% 
Enox
N/A
3.0% Riv; 2.5% 
Enox
RECORD1-4 
(US FDA, 
2009)
12383 Hip and Knee 10-39
Riv 10-QD; 
Enox 40-QD 
or 30-BID
3.19% Riv; 2.55% 
Enox
1.8% Riv; 1.37% 
Enox
N/A
APROPOS 
(Lassen, 
2007)
1217 Knee 10-14
Apix 5-, 10-, 
20-QD; 2.5-, 
5-, 10-BID; 
Enox 30-BID 
or Warfarin 
(INR 1.8-3.0)
0% Apix 2.5-BID; 
1.3% Enox; 0% 
Warfarin
N/A N/A
ADVANCE-1 
(Lassen, 
2009)
3184 Knee 10-14
Apix 2.5-BID; 
Enox 30-BID
2.9% Apix; 4.3% 
Enox
0.5% Apix; 0.9% 
Enox
2.2% Apix; 3.0% 
Enox
ADVANCE-2 
(Lassen, 
2010b)
3009 Knee 10-14
Apix 2.5-BID; 
Enox 40-QD
3.5% Apix; 4.8% 
Enox
0.5% Apix; 0.7% 
Enox
2.9% Apix; 3.8% 
Enox
ADVANCE-3 
(Lassen, 
2010a)
5332 Hip N/A
Apix 2.5-BID; 
Enox 40-QD
4.8% Apix; 5.0% 
Enox
0.7% Apix; 0.6% 
Enox
4.1% Apix; 4.5% 
Enox
Rivaroxaban 
(Riv)
Dabigatran 
etexilate 
(Dab)
Apixaban 
(Apix)
 
Table 3. Major bleeding rates in VTE prophylaxis clinical trails in THA and TKA. (Reference: 
Huo, M. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic 
patients: Are they really better? Thromb Haemost 2011;106:45-57. 
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6. Conclusion 
VTE remains a challenging problem that complicates many orthopaedic procedures. The 
incidence has been found to be particularly high following TKA and THA. Governmental 
and consumer governing bodies are beginning to recognize it as a “never-event” indicating 
that increased emphasis will be placed on prophylaxis in the years to come. 
Recommendations have been released by both the ACCP and the AAOS and there remains 
some disagreement as to the optimal management of VTE. Warfarin and LMWH remain the 
standard of care in many practices, but newer agents show increasing promise. 
The authors have several recommendations regarding the duration and type of therapy. 
Patients should be anticoagulated for 25-30 days postoperatively following total hip 
arthroplasty and for 14 days following a total knee arthroplasty. Certain patients with high 
risk of VTE (obese, low mobility, prior VTE, family history of VTE, or protein C/S 
deficiency) should be treated for 25-30 days as well following hip or knee replacement. At 
our institution, we generally use enoxaparin for postoperative anticoagulation. For 
inpatients, either 30mg twice daily or 40mg daily may be used following total hip 
arthroplasty. The FDA has approved only the twice daily dosing after total knee 
arthroplasty. For outpatients, enoxaparin 40mg daily is our regimen of choice. 
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